Johnston Erwin, TRexBio CEO
November 13, 2024 07:00 AM EST
Financing

TRexBio rais­es $84M to take in-house im­mune pro­gram in­to the clin­ic

Lei Lei Wu

News Reporter

Bay Area im­munol­o­gy biotech TRexBio has raised a $84 mil­lion Se­ries B to start clin­i­cal stud­ies of a po­ten­tial treat­ment for atopic der­mati­tis and ul­cer­a­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times